Aclarion (NASDAQ:ACON) Price Target Cut to $1.30 by Analysts at Ascendiant Capital Markets

Aclarion (NASDAQ:ACON) had its price target lowered by Ascendiant Capital Markets from $1.50 to $1.30 in a research report sent to investors on Wednesday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Aclarion Stock Performance

Shares of NASDAQ ACON opened at $0.18 on Wednesday. The company has a 50-day moving average price of $0.18 and a 200-day moving average price of $0.24. Aclarion has a 1 year low of $0.16 and a 1 year high of $7.40.

Institutional Investors Weigh In On Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC acquired a new stake in Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion at the end of the most recent quarter. 7.52% of the stock is owned by hedge funds and other institutional investors.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.